ACE-031 Research Guide

Full name: ACE-031 (Soluble ActRIIB-Fc Fusion)

A soluble ActRIIB-Fc fusion acting as ligand trap for myostatin, activin, and GDF-11. Removes multiple negative regulators of muscle growth simultaneously.

How ACE-031 Works

Decoy receptor sequestering TGF-B ligands (myostatin, activin, GDF-11) in bloodstream, preventing cell-surface ActRIIB binding and removing multiple anabolic brakes.

Dosing Protocol

• Typical dose: 0.3-3 mg/kg
• Frequency: Every 2-4 weeks
• Duration: 12-24 weeks
• Route: Subcutaneous

Reported Benefits

• Multi-ligand pathway inhibition
• Lean mass increase
• Bone density increase
• Infrequent dosing
• Functional strength improvement

Potential Side Effects

• Epistaxis
• Gum bleeding
• Telangiectasia
• Vascular effects
• Development halted for DMD

Research Citations

1. ACE-031 in Duchenne muscular dystrophy (2019) - Increased lean body mass by 5% in 12 weeks; halted due to bleeding/vascular events.
2. ActRIIB decoy receptors for cancer cachexia (2021) - Reversed cancer muscle wasting by 30% and improved grip strength without tumor effects.

Related Muscle Growth Compounds

• Follistatin 344 - Full Profile
• IGF-1 LR3 - Full Profile
• MGF (Mechano Growth Factor) - Full Profile
• Myostatin Inhibitor - Full Profile
• LGD-4033 - Full Profile
• YK-11 - Full Profile

View full ACE-031 profile with 3D molecule viewer →